What do Analysts Say about Hormel Foods Corporation(NYSE:HRL) and Acasti Pharma, Inc.(NASDAQ:ACST)

0
8

Hormel Foods Corporation (HRL) will report its next earnings on Feb 19 BMO. The company reported the earnings of $0.51/Share in the last quarter where the estimated EPS by analysts was $0.49/share. The difference between the expected and actual EPS was $0.02/share, which represents an Earnings surprise of 4.1%.

Many analysts are providing their Estimated Earnings analysis for Hormel Foods Corporation and for the current quarter 12 analysts have projected that the stock could give an Average Earnings estimate of $0.44/share. These analysts have also projected a Low Estimate of $0.41/share and a High Estimate of $0.47/share.

In case of Revenue Estimates, 10 analysts have provided their consensus Average Revenue Estimates for Hormel Foods Corporation as 2.39 Billion. According to these analysts, the Low Revenue Estimate for Hormel Foods Corporation is 2.32 Billion and the High Revenue Estimate is 2.44 Billion. The company had Year Ago Sales of 2.33 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for HRL to be -2.3%. They are projecting Next Quarter growth of 4.55%. For the next 5 years, Hormel Foods Corporation is expecting Growth of 7.58% per annum, whereas in the past 5 years the growth was -2.65% per annum.

Some buy side analysts are also providing their Analysis on Hormel Foods Corporation, where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 2 said it’s a HOLD, and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Hormel Foods Corporation might touch $50 high while the Average Price Target and Low price Target is $40.08 and $33 respectively.

Hormel Foods Corporation closed its last trading session at $42.65 with the gain of 1.41%. The Market Capitalization of the company stands at 22.92 Billion. The Company has 52-week high of $46.26 and 52-week low of $31.71. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 0.89% where SMA50 and SMA200 are -1.48% and 10.74% respectively. The Company Touched its 52-Week High on 11/19/18 and 52-Week Low on 02/06/18.

The Relative Volume of the company is 1.11 and Average Volume (3 months) is 3.41 million. The company’s P/E (price to earnings) ratio is 25.04 and Forward P/E ratio of 22.16.

The company shows its Return on Assets (ROA) value of 12.8%. The Return on Equity (ROE) value stands at 18.9%. While it’s Return on Investment (ROI) value is 15.4%.

While looking at the Stock’s Performance, Hormel Foods Corporation currently shows a Weekly Performance of 3.77%, where Monthly Performance is -2.28%, Quarterly performance is 6.21%, 6 Months performance is 15.27% and yearly performance percentage is 18.82%. Year to Date performance value (YTD perf) value is 1.34%. The Stock currently has a Weekly Volatility of 2.12% and Monthly Volatility of 2.47%.

Acasti Pharma, Inc. (ACST) will report its next earnings on Feb 13 BMO. The company reported the earnings of $-0.31/Share in the last quarter where the estimated EPS by analysts was $-0.24/share. The difference between the expected and actual EPS was $-0.07/share, which represents an Earnings surprise of -29.2%.

Many analysts are providing their Estimated Earnings analysis for Acasti Pharma, Inc. and for the current quarter 1 analysts have projected that the stock could give an Average Earnings estimate of $-0.16/share. These analysts have also projected a Low Estimate of $-0.16/share and a High Estimate of $-0.16/share.

These analysts also forecasted Growth Estimates for the Current Quarter for ACST to be 74.2%. They are projecting Next Quarter growth of 91.67%. For the next 5 years, Acasti Pharma, Inc. is expecting Growth of 51.85% per annum, whereas in the past 5 years the growth was 28.95% per annum.

Some buy side analysts are also providing their Analysis on Acasti Pharma, Inc., where 1 analysts have rated the stock as Strong buy, 2 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Acasti Pharma, Inc. might touch $8.7 high while the Average Price Target and Low price Target is $4.53 and $2.4 respectively.

Acasti Pharma, Inc. closed its last trading session at $1.05 with the gain of 4.76%. The Market Capitalization of the company stands at 85.94 Million. The Company has 52-week high of $1.80 and 52-week low of $0.43. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 42.03% where SMA50 and SMA200 are 37.74% and 42.37% respectively. The Company Touched its 52-Week High on 10/01/18 and 52-Week Low on 08/13/18.

The Relative Volume of the company is 1.19 and Average Volume (3 months) is 701.63 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of 0%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Acasti Pharma, Inc. currently shows a Weekly Performance of 26.02%, where Monthly Performance is 69.99%, Quarterly performance is -11.29%, 6 Months performance is 86.47% and yearly performance percentage is 15.79%. Year to Date performance value (YTD perf) value is 32.23%. The Stock currently has a Weekly Volatility of 7.87% and Monthly Volatility of 8.33%.

SHARE